| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.00 | 100.0% |
| Total Income | 0.00 | 100.0% |
| Expenditure | 44.26 | 22.9% |
| PBT | — | |
| Net Profit | -24.15 | 53.7% |
| OPM | — | |
| NPM | — | |
| EPS | -1.10 | 511.1% |
Lyell Immunopharma Reports Q1 2026 Financial Results
07 May 2026 · 7 May, 1:48 am
Summary
Lyell Immunopharma, Inc. reported its financial results and business highlights for the first quarter ended March 31, 2026. The company reported a net loss of $24.2 million, a decrease from the $52.2 million net loss in the same period of 2025. Research and development expenses decreased to $36.6 million from $43.4 million year-over-year. The company's cash, cash equivalents, and marketable securities totaled $261.0 million as of March 31, 2026, and are expected to provide runway into Q3 2027.
Key Highlights
- 1
Lyell Immunopharma reported a net loss of $24.2 million for the first quarter ended March 31, 2026, compared to a net loss of $52.2 million for the same period in 2025.
- 2
Research and development expenses were $36.6 million for the first quarter ended March 31, 2026, compared to $43.4 million for the same period in 2025.
- 3
General and administrative expenses were $9.6 million for the first quarter ended March 31, 2026 compared to $14.0 million for the same period in 2025.
- 4
Cash, cash equivalents and marketable securities as of March 31, 2026 were $261.0 million compared to $247.2 million as of December 31, 2025.
- 5
The company closed the second $50 million tranche of its July 2025 equity private placement at $25.61 per share.
- 6
Patient dosing commenced in PiNACLE-H2H, a Phase 3 clinical trial evaluating ronde-cel against standard-of-care CD19 CAR T-cell therapies in the LBCL second-line setting.
- 7
The U.S. Phase 1 clinical trial of LYL273 continues to enroll patients with metastatic colorectal cancer, with commencement of patient dosing at Dose Level 3.
Informational and educational content only. Not investment advice.